Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- PEGA +26.7%, BPOP +18.5%, VRT +18.3%, SAP +8.6%, BSX +7.4%, TSLA +7.3%, GEV +6.5%, MANH +6.3% (also replenishes buyback authorization to $100 mln), UMC +5.9%, TEL +5.5%, RRC +5.1%, HCSG +4.7%, VBTX +4.2% (also increases dividend), T +4.2%, PM +4.1%, ISRG +3.8%, ZWS +3.8%, CHKP +3.5%, ODFL +3.2%, CASH +3.1%, COF +3% (also reports March card metrics), STLD +2.5%, TMHC +2.1%, VIRT +2%, WAB +1.9%
Other news:
- SMMT +9.9% (noted that Akeso announced that the Phase III clinical trial, HARMONi-6 or AK112-306, met its primary endpoint of progression-free survival)
- IPHA +9.2% (regains its rights on CD123 Targeting ANKET; Sanofi (SNY) intends to make a strategic investment in the Co)
- GRAL +7.8% (to present new data on Galleri)
- GOGL +7% (CMBT and GOGL to merge)
- RXRX +6.4% (to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025)
- WDS +4.6% (reports Q1 production)
- KAR +3.7% (names new CFO)
- TOI +3.3% (expands partnership with Helios)
- VNO +3.3% (announces PENN 1 ground rent reset determination)
- ERJ +3.2% (reports Q1 backlog)
- MET +2.2% (increases dividend)
Analyst comments:
- CAVA +5.8% (upgraded to Outperform from Market Perform at Bernstein)
- TOST +5% (upgraded to Outperform from Peer Perform at Wolfe Research)
- AXP +3.6% (upgraded to Neutral from Sell at Redburn Atlantic)
- RTX +2.7% (upgraded to Overweight from Equal Weight at Morgan Stanley)
- INTU +2.3% (upgraded to Buy from Hold at HSBC)